A naturally derived lipopeptide lipid nanoparticle platform enabling multiple nucleic acids delivery.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41268339.
- Also identified by DOI 10.1016/j.bioactmat.2025.09.007 and PMC identifier 12628137.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lipid nanoparticles (LNPs) have emerged as versatile platforms for nucleic acid-based therapies. Despite advancements, key challenges remain in achieving tissue-specific delivery while maintaining low toxicity and tunable properties essential for therapeutic applications. Here, we report a novel high-performance LNP platform employing arginine-histidine peptide-dioleoylphosphatidylethanolamine (RmHnC-DOPE) lipopeptides as core components. Through systematic optimization of arginine-to-histidine ratios, we engineered three variants, R3H7C-DOPE, R4H6C-DOPE, and R5H5C-DOPE, enabling payload-specific and tissue-selective delivery of siRNA, mRNA, and plasmid DNA. <i>In vitro</i> evaluation demonstrated superior gene silencing efficiency for R4H6C-DOPE (85.1%) and R5H5C-DOPE (89.5%) compared to benchmark SM-102 LNPs (67.4%), while maintaining >99% cell viability. R5H5C-DOPE exhibited exceptional broad-spectrum delivery, achieving 74.8% and 92.1% transfection efficiency for mRNA and pDNA, respectively. Notably, R3H7C-DOPE showed 11-fold enhanced pDNA expression relative to SM-102. <i>In vivo</i> studies revealed R3H7C-DOPE's superior hepatic targeting, achieving >2-fold greater PCSK9 suppression (14.1 ± 7.3% residual expression at day 28) versus SM-102 (53.8 ± 41.2% at day 7). R5H5C-DOPE demonstrated remarkable extrahepatic targeting with >90% pulmonary localization, effectively overcoming the hepatic tropism of conventional LNPs. Comprehensive safety assessments revealed exceptional biocompatibility of RmHnC-DOPE formulations, with 100% survival rates across mouse strains, contrasting sharply with SM-102-induced severe toxicity and mortality. Long-term studies confirmed sustained tolerability with preserved organ function and minimal inflammatory responses. This versatile platform combines superior biocompatibility, precise tissue targeting, and synthetic accessibility, providing a clinically viable solution for diverse gene delivery applications spanning hepatic silencing and extrahepatic therapeutics.